Endostar (25 μg/ml) inhibited the expression of HIF-1 with the upregulation of MHC class I α-heavy chain and β2 m light chain in A549 and NCI-H1299 lung cancer cells, which showed the potential for Endostar to facilitate cancer immunotherapy. The gene discussed is HIF1A; the disease is lung carcinoma.